ALXO ALX Oncology Holdings Inc.

27d ago, source: Seeking Alpha

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept ...

ALX Oncology Holdings Inc (ALXO) Insider Sells Shares

13d ago, source: Yahoo Finance

Jaume Pons, PRESIDENT & Chief Scientific Officer of ALX Oncology Holdings Inc (NASDAQ:ALXO), sold 20,000 shares of the ...

Buy Rating on ALX Oncology Holdings Amid Strong Clinical Data and Favorable rNPV Analysis

9d ago, source:

ALX Oncology Holdings (ALXO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study

8d ago, source: Zacks.com on MSN

ALX Oncology Holdings Inc. ALXO reported positive results from an ongoing phase I/II investigator-sponsored study of evorpacept, in combination with Roche’s RHHBY Rituxan (rituximab) and Bristol Myers ...

ALX Oncology’s Evorpacept Shows Promising Potential in Cancer Treatment Studies

1mon ago, source: Business Insider

ALX Oncology Holdings (ALXO) Company Description: ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company. The firm is focused on developing therapies that block the CD47 checkpoint ...

ALX Oncology Announces Upcoming Investor Conference Participation

29d ago, source: ADVFN

ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that ...

ALX Oncology Holdings, Inc.

6mon ago, source: CNN

ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for ...

Alx Oncology Holdings (ALXO)

1mon ago, source: Investing

In a recent transaction, Jaume Pons, the President and Chief Scientific Officer (CSO) of ALX Oncology Holdings Inc. (NASDAQ:ALXO), sold 20,000 shares of the company’s common... ALX Oncology ...

ALX Oncology Holdings Inc.

6mon ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

ALX Oncology Holdings Inc Ordinary Shares

15d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

ALX Oncology Holdings Inc.

6mon ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...